Literature DB >> 16520806

Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.

Stephanie Halene1, Arthur Zieske, Nancy Berliner.   

Abstract

BACKGROUND: A 73-year-old woman presented with acute lower back pain, fever, chills and arthralgias. She had previously had a positive protein derivative test with a negative chest X-ray; her medical history was also remarkable for a mitral valve prolapse. Initial symptoms resolved spontaneously without therapy, but fever recurred with associated arthralgias, myalgias, diffuse and worsening lymphadenopathy, splenomegaly, and bilateral pulmonary infiltrates. INVESTIGATIONS: Physical examination, blood and urine cultures, MRI of the spine, echocardiogram, extensive serologies, serum and urine protein electrophoresis, immunofixation electrophoresis, bone-marrow aspiration and biopsy with flow cytometry, cytogenetics, and gene rearrangement studies, CT scan of the chest, abdomen and pelvis, whole-body PET, and lymph-node biopsy for histological examination, immunohistochemistry, and gene rearrangement studies. DIAGNOSIS: Angioimmunoblastic T-cell lymphoma. MANAGEMENT: Steroids (prednisone, methylprednisolone), levofloxacin, isoniazid with pyridoxine, ciclosporin A, methotrexate, alemtuzumab, broad-spectrum antibiotics, Pneumocystis carinii prophylaxis, vancomycin, and clindamycin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520806     DOI: 10.1038/ncponc0430

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  3 in total

Review 1.  New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Authors:  Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

2.  Spontaneous complete remission of angioimmunoblastic T-cell lymphoma.

Authors:  Michael S Humeniuk; Jackson J Liang; Matthew Howard; David J Inwards
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-07

3.  The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.

Authors:  Jew Win Kuan; Kian Meng Chang; Ngee Siang Lau; Purushothaman Visalachy; Sen Mui Tan; Tee Chuan Ong; Anselm Ting Su
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-05       Impact factor: 0.900

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.